FMP

FMP

Enter

CRNX - Crinetics Pharm...

photo-url-https://images.financialmodelingprep.com/symbol/CRNX.png

Crinetics Pharmaceuticals, Inc.

CRNX

NASDAQ

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

57.69 USD

0.58 (1.01%)

Historical Prices

From:

To:

We are unable to load the chart at this time.

fmp-logo

About

ceo

Dr. R. Scott Struthers Ph.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsu...

CIK

0001658247

ISIN

US22663K1079

CUSIP

22663K107

Address

Building No. 2

Phone

858 450 6464

Country

US

Employee

290

IPO Date

Jul 18, 2018

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

CRNX Financial Summary

CIK

0001658247

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

22663K107

ISIN

US22663K1079

Country

US

Price

57.69

Beta

0.62

Volume Avg.

716.7k

Market Cap

5.35B

Shares

-

52-Week

32.555-62.53

DCF

-5.43

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-15.59

P/B

-

Website

https://www.crinetics.com

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

Latest CRNX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep